Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease

Experimental Gerontology

Volumn 50, Issue 1, 2014, Pages 95-105

  Van Kampen, Jackalina M ^a,b   Baranowski, David B ^a   Shaw, Christopher A ^c   Kay, Denis G ^a,b  

^a Neurodyn Inc   (Canada)

^b UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Synuclein; BSSG; Dopamine; G115; Ginseng; Neuroprotection; Parkinson's disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; GINSENG EXTRACT; SITOGLUSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CLINICAL FEATURE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; FEMALE; GLIOSIS; HISTOPATHOLOGY; LOCOMOTION; MOTOR COORDINATION; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; RAT MODEL;

BSSG; DAT; DOPAMINE; DOPAMINE TRANSPORTER; ENDOPLASMIC RETICULUM; ER; G115; GINSENG; GLUCOSE-REGULATED PROTEIN; GRP; NEUROPROTECTION; PARKINSON'S DISEASE; PD; SNC; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE DUTP NICK END LABELING; TH; TUNEL; TYROSINE HYDROXYLASE; UNFOLDED PROTEIN RESPONSE; UPR; Α-SYNUCLEIN; Β-SITOSTEROL Β-D-GLUCOSIDE;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENCEPHALITIS; FEMALE; GAIT DISORDERS, NEUROLOGIC; NEUROPROTECTIVE AGENTS; PANAX; PARKINSON DISEASE, SECONDARY; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SITOSTEROLS; SUBSTANTIA NIGRA;

EID: 84890578671     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.11.012     Document Type: Article

References (70)

1. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K., Nelson J.S., Curb J.D., Petrovitch H. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
2. Adler C.H. Premotor symptoms and early diagnosis of Parkinson's disease. Int. J. Neurosci. 2011, 121:3-8.
3. Attele A.S., Wu J.A., Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58:1685-1693.
4. Chen X.C., Zhu Y.G., Zhu L.A., Huang C., Chen Y., Chen L.M., Fang F., Zhou Y.C., Zhao C.H. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur. J. Pharmacol. 2003, 473:1-7.
5. Chen X.C., Zhou Y.C., Chen Y., Zhu Y.G., Fang F., Chen L.M. Ginsenosdie Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Yao Xue Xue Bao 2005, 26:56-62.
6. Chen X.C., Zhou Y.C., Chen Y., Zhu Y.G., Fang F., Chen L.M. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Yao Xue Xue Bao 2005, 26:56-62.
7. Cho I.H. Effects of Panax ginseng in neurodegenerative diseases. J. Ginseng Res. 2012, 36:342-353.
8. Coon J.T., Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002, 25:323-344.
9. Currais A., Maher P. Functional consequences of age-dependent changes in glutathione status in the brain. Antioxid. Redox Signal. 2013, 19(8):813-822. (Epub ahead of print).
10. Fang F., Chen X., Huang T., Lue L.F., Luddy J.S., Yan S.S. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim. Biophys. Acta 2012, 1822:286-292.
11. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5104-5108.
12. Gage H., Kaye J., Kimber A., Storey L., Egan M., Qiao Y., Trend P. Correlates of constipation in people with Parkinson's. Parkinsonism Relat. Disord. 2011, 17:106-111.
13. Gao X., Chen H., Schwarzschild M.A., Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am. J. Epidemiol. 2011, 174:546-551.
14. Gu B., Nakamichi N., Zhang W.S., Nakamura Y., Kambe Y., Fukumori R., Takuma K., Yamada K., Takarada T., Taniura H., Yoneda Y. Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-d-aspartate receptors composed of an NR1/NR2B subunit assembly. J. Neurosci. Res. 2009, 87:2145-2156.
15. Haehner A., Boesveldt S., Berendse H.W., Mackay-Sim A., Fleishchmann J., Silburn P.A., Johnston A.N., Mellick G.D., Herting B., Reichmann H., Hummel T. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat. Disord. 2009, 15:490-494.
16. He B., Chen P., Yang J., Yun Y., Zhang X., Yang R., Shen Z. Neuroprotective effect of 20(R)-ginsenoside Rg(3) against transient focal cerebral ischemia in rats. Neurosci. Lett. 2012, 526:106-111.
17. Huang K.C., Williams W.M. The Pharmacology of Chinese Herbs 1999, CRC.
18. Ishihar L., Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol. Scand. 2006, 113:211-220.
19. Jiang F., De Silva S., Turnbull J. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J. Neurol. Sci. 2000, 180:52-54.
20. Jiang B., Xiong Z., Yang J., Wang W., Wang Y., Hu Z.L., Wang F., Chen J.G. Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br. J. Pharmacol. 2012, 166:1872-1887.
21. Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999, 13:1211-1233.
22. Khabazian I., Bains J.S., Williams D.E., Cheung J., Wilson J.M., Pasqualotto B.A., Pelech S.L., Andersen R.J., Wang Y.T., Liu L., Nagai A., Kim S.U., Craig U.K., Shaw C.A. Isolation of various forms fo sterol beta-d-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex. J. Neurochem. 2002, 82:516-528.
23. Kim J.H., Cho S.Y., Lee J.H., Jeong S.M., Yoon I.S., Lee B.H., Lee J.H., Pyo M.K., Lee S.M., Chung J.M., Kim S., Rhim H., Oh J.W., Nah S.Y. Neuroprotective effects of ginsenoside Rg3 against homocysteine-induced excitotoxicity in rat hippocampus. Brain Res. 2007, 1136:190-199.
24. Kim K.H., Song K., Yoon S.H., Shehzad O., Kim Y.S., Son J.H. Rescue of PINK1 protein null-specific mitochondrial complex IV deficits by ginsenoside Re activation of nitric oxide signaling. J. Biol. Chem. 2012, 287:44109-44120.
25. Kim E.J., Jung I.H., Van Le T.K., Jeong J.J., Kim N.J., Kim D.H. Ginsenosodes Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. J. Ethnopharmacol. 2013, 146:294-299.
26. Lam P.Y., Yin F., Hamilton R.T., Boveris A., Cadenas E. Elevated neuronal nitric oxide synthase expression during ageing and mitochondrial energy production. Free Radic. Res. 2009, 43:431-439.
27. Lee A.S. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005, 35:373-381.
28. Lee J.S., Choi H.S., Kang S.W., Chung J.H., Park H.K., Ban J.Y., Kwon O.Y., Hong H.P., Ko Y.G. Therapeutic effect of Korean red ginseng on inflammatory cytokines in rats with focal cerebral ischemia/reperfusion injury. Am. J. Chin. Med. 2011, 39:83-94.
29. Lee J.S., Song J.H., Sohn N.W., Shin J.W. Inhibitory effects of ginsenoside Rb1 on neuroinflammation following systemic lipopolysaccharide treatment in mice. Phytother. Res. 2012, 27(9):1270-1276. (Epub ahead of print).
30. Lee K.W., Jung S.Y., Choi S.M., Yang E.J. Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells. BMC Complement. Alternat. Med. 2012, 12:196.
31. Lee N.H., Yoo S.R., Kim H.G., Cho J.H., Son C.G. Safety and tolerability of Panax ginseng root extract: a randomized, placebo-controlled trial in healthy Korean volunteers. J. Altern. Complement. Med. 2012, 18:1061-1069.
32. Liang W., Ge S., Yang L., Yang M., Ye Z., Yan M., Du J., Luo Z. Ginsenosides Rb1 and Rg1 promote proliferation and expression of neurotrophic factors in primary Schwann cell cultures. Brain Res. 2010, 1357:19-25.
33. Lin W.M., Zhang Y.M., Moldzio R., Rausch W.D. Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture. J. Neural Transm. 2007, 105-112. (Suppl.).
34. Luo F.C., Wang S.D., Qi L., Song J.Y., Lv T., Bai J. Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. J. Ethnopharmacol. 2011, 133:448-453.
35. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci. 2005, 28:57-87.
36. Nah S.Y., Bhatia K.S., Lyles J., Ellinwood E.H., Lee T.H. Effects of ginseng saponin on acute cocaine-induced alterations in evoked dopamine release and uptake in the rat brain nucleus accumbens. Brain Res. 2009, 1248:184-190.
37. Noyce A.J., Bestwick J.P., Silveira-Moriyama L., Hawkes C.H., Giovannoni G., Lees A.J., Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 2012, 72:893-901.
38. Pagan F.L. Improving outcomes through early diagnosis of Parkinson's disease. Am. J. Manage Care 2012, 18:S176-S182.
39. Park S.M., Choi M.S., Sohn N.W., Shin J.W. Ginsenoside Rg3 attenuates microglia activation following systemic lipopolysaccharide treatment in mice. Biol. Pharm. Bull. 2012, 35:1546-1552.
40. Paul S., Shin H.S., Kang S.C. Inhibition of inflammations and macrophage activation by ginsenoside-Re isolated from Korean ginseng (Panax ginseng C.A. Meyer). Food and Chemical. Toxicology 2012, 50:1354-1361.
41. Pizza V., Agresta A., D'Acunto C.W., Festa M., Capasso A. Neuroinflammation and ageing: current theories and an overview of the data. Rev. Recent Clin. Trials 2011, 6:189-203.
42. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
43. Postuma R.B., Gagnon J.F., Montplaisir J. Clinical prediction of Parkinson's disease-planning for the age of neuroprotection. J. Neurol. Neurosurg. Psychiatry 2010, 81:1008-1013.
44. Rolheiser T.M., Fulton H.G., Good K.P., Fish J.D., McKelvey J.R., Scherfler C., Khan N.M., Leslie R.A., Robertson H.A. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. J. Neurol. 2011, 258:1254-1260.
45. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Poppler J., Masaki K., Launer L., White L.R. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 2008, 63:167-173.
46. Schulz J.D., Hawkes E.L., Shaw C.A. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator. Med. Hypotheses 2006, 66:1222-1226.
47. Shen W.B., McDowell K.A., Siebert A.A., Clark S.M., Dugger N.V., Valentino K.M., Jinnah H.A., Sztalryd C., Fishman P.S., Shaw C.A., Jafri M.S., Yarowsky P.J. Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann. Neurol. 2010, 68:70-80.
48. Shin Y.M., Jung H.J., Choi W.Y., Lim C.J. Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol. Biol. Rep. 2013, 40:269-279.
49. Siderowf A., Lang A.E. Premotor Parkinson's disease: concepts and definitions. Mov. Disord. 2012, 27:608-616.
50. Siderowf A., Jennings D., Eberly S., Oakes D., Hawkins K.A., Ascherio A., Stern M.B., Marek K., Investigators P. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov. Disord. 2012, 27:406-412.
51. Singh S., Ahmad R., Mathur D., Sagar R.K., Krishana B. Neuroprotective effect of BDNF in yound and aged 6-OHDA treated rat model of Parkinson disease. Indian J. Exp. Biol. 2006, 44:699-704.
52. Spencer L.R., Lasarev M.R., Palmer V.S., Kisby G.E. Neurotoxic cycad componenets and Western Pacific ALS/PDC. Ann. Neurol. 2010, 68:975-976.
53. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-Synuclein in Lewy bodies. Nature 1997, 388:839-840.
54. Tabata R., Wilson J.M., Ly P., Kwok D., Van Kampen J.M., Cashman N., Shaw C.A. Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. NeuroMolecular Med. 2008, 10:24-39.
55. Tsang D., Yeung H.W., Tso W.W., Peck H. Ginseng saponins: influence on neurotransmitter uptake in rat brain synaptosomes. Planta Med. 1985, 51:221-224.
56. Tsang D., Yeung H.W., Tso W.W., Peck H. Ginseng sponins influence on neurotransmitter uptake in rat brain synaptosomes. Planta Med. 1985, 3:221-224.
57. Tsukahara T., Takeda M., Shimohama S., Ohara O., Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995, 37:733-739.
58. Van Kampen J.M., Robertson H.A., Hagg T., Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. Exp. Neurol. 2003, 184:521-529.
59. Van Kampen J.M., Baranowski D.C., Shaw C.A., Kay D.G. Abstracts of the Third World Parkinson Congress, October 1-4, 2013, Montreal, Canada. J. Parkinson's Dis. 2013, 3:3-252.
60. Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27:494-506.
61. Wang Y., Feng Y., Fu Q., Li L. Panax notoginsenoside Rb1 ameliorates Alzheimer's disease by regulating brain-derived neurtotrophic factor and downregulating Tau protein expression. Exp. Ther. Med. 2013, 6:826-830.
62. Wilson J.M., Khabazian I., Wong M.C., Seyedalikhani A., Bains J.S., Pasqualotto B.A., Williams D.E., Andersen R.J., Simpson R.J., Smith R.G., Craig U.K., Kurland L.T., Shaw C.A. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. NeuroMolecular Med. 2002, 1:207-221.
63. Wu J., Jeong H.K., Bulin S.E., Kwon S.W., Park J.H., Bezprozvanny I. Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. J. Neurosci. Res. 2009, 87:1904-1912.
64. Xu L., Chen W.F., Wong M.S. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-1 receptor signalling pathway. Br. J. Pharmacol. 2009, 158:738-748.
65. Ye R., Zhao G., Liu X. Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside. Expert. Rev. Neurother. 2013, 13:603-613.
66. Yin F., Boveris A., Cadenas E. Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 2012, (Epub ahead of print).
67. Yoshimoto Y., Lin Q., Collier T.J., Frim D.M., Breakefield X.O., Bohn M.C. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res. 1995, 691:25-36.
68. Youdim M.B.H., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005, 26:27-35.
69. Yu S.C., Li X.Y. Effect of ginsenoside on IL-1 beta and IL-6 mRNA expression in hippocampal neurons in chronic inflammation model of aged rats. Acta Pharmacol. Sin. 2000, 21:915-918.
70. Zhang C., Du F., Shi M., Ye R., Cheng H., Han J., Ma L., Cao R., Rao Z., Zhao G. Ginsenoside Rd protects neurons against glutamate-induced excitotoxicity by inhibiting Ca(2+) influx. Cell. Mol. Neurobiol. 2012, 32:121-128.